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Presymptomaticsis (ALS) is primarily a motor neuron disorder. Intriguingly, early muscle
denervation preceding motor neuron loss is observed in mouse models of ALS. Enhanced muscle
vulnerability to denervation process has been suggested by accelerated muscle deterioration following
peripheral nerve injury in an ALS mouse model. Here we provide evidence of biochemical changes in the
hindlimb muscle of young, presymptomatic G93A hSOD1 transgenic mice. In this report, we demonstrate
that cdk5 activity is reduced in hindlimb muscle of 27-day-old G93A hSOD1 transgenic mice. In vitro analysis
revealed mutant hSOD1-mediated suppression of cdk5 activity. Furthermore, the decrease in muscle cdk5
activity was accompanied by a signiﬁcant reduction in MyoD and cyclin D1 levels. These early muscle
changes raise the possibility that the progressive deterioration of muscle function is potentiated by altered
muscle biochemistry in these mice at a very young, presymptomatic age.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegen-
erative disorder affecting the upper and lower motor neurons. Motor
neuron degeneration is accompanied by muscle weakness and
paralysis with an inevitably fatal outcome. Approximately 90% of ALS
cases are sporadic, with mutations in the Cu/Zn superoxide dismutase
1 (SOD1) gene accounting for 20% of the familial cases [1–3]. Over-
expression of various mutant isoforms of human SOD1 (hSOD1) in
mice simulates the major pathological hallmarks of ALS, conﬁrming
the signiﬁcant role of mutant hSOD1 in ALS pathology, and resulting in
one of the most convincing mouse models of a human disease [4–6].
Accumulating evidence highlights the inﬂuence of non-neuronal
neighboring cells and local microenvironment on motor neuron
degeneration [7]. A study examining chimeric mice that are mixtures
of normal and mutant hSOD1-expressing cells has shown that
neighboring wildtype non-neuronal cells are capable of rescuing
motor neurons expressing mutant hSOD1 [8]. Recently, the deleter-
ious inﬂuence of mutant hSOD1 expressing astrocyte andmicroglia on
motor neuron survival have been reported [9–11]. In contrast, siRNA-ll rights reserved.mediated knock-down and Cre recombinase-mediated knock-out of
mutant hSOD1 in the skeletal muscles of transgenic mice did not affect
the disease progression, leading the authors to conclude that the
muscle does not play a primary role in mutant hSOD1mediatedmotor
neuron toxicity [12]. However, even without a direct involvement in
mutant hSOD1-mediated motor neuron toxicity, could there be an
underlying muscle condition that contributes to and/or enhances the
muscle function deterioration resulting from denervation in these
mice? Intact muscle and nerve connection is important for the muscle
and motor neuron function and their survival [13]. It is unclear
whether there is an underlying intrinsic muscle impairment that
contributes to the muscle function loss in ALS.
While a signiﬁcant loss of motor neurons is not observed until
approximately 90 days of age in G93A hSOD1 transgenic mice (G93A
hSOD1mice) [14], denervation of neuromuscular junctions is detected
as early as 47 days of age [15–19]. Interestingly, Bax deletion-mediated
rescue of motor neurons in G93A hSOD1 mice fails to prevent this
early neuromuscular denervation [20] suggesting that the denerva-
tion in these animals precedes and is independent of motor neuron
loss. Additionally, peripheral nerve injury results in an accelerated
appearance of disease symptoms in hindlimb muscle of G93A hSOD1
mice, suggestive of increased muscle vulnerability in response to
denervation in this model [21].
The potential role of muscle in ALS is highlighted by the thera-
peutic beneﬁt of muscle-targeted expression of either IGF-1 or GDNF
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progression [22–24]. IGF-1 is a classic mitogen and its muscle
expression has been shown to facilitate muscle and motor neuron
regeneration [25] and muscle hypertrophy [26]. The mechanism
underlying disease amelioration mediated by muscle-targeted IGF-1
in the ALS mouse model is not known. Although the muscle mass
increase resulting from myostatin inhibition treatment initiated at
28 days of age did not have an effect on animal survival, the treatment
led to increased motor neuron survival around 84–90 days of age and
delayed muscle atrophy in G93A hSOD1 mice [27]. On the other hand,
induction of muscle hypertrophy via virally-mediated overexpression
of follistatin in the hindlimbs of G93A hSOD1 mice improved muscle
strength but did not improve rotarod performance [12].
To determine whether early biochemical changes are present in
the muscle of G93A hSOD1 mice, we examined cyclin dependent
kinase 5 (cdk5) activity in triceps surae samples from young, pre-
symptomatic mice. Cdk5 is a proline-directed serine/threonine kinase
that is involved in numerous cellular functions in the central nervous
system [28,29]. It is also implicated in various aspects of muscle
function such as acetylcholine receptor clustering [30–32] and
myogenesis [33,34]. Cdk5 activity is also upregulated in the muscle
following denervation [35].
Here we report decreased cdk5 activity in the hindlimb muscle of
27-day-old G93A hSOD1 mice. This decreased activity was accom-
panied by increased interaction of cdk5 with mutant hSOD1 in the
muscle. In vitro analysis revealed that the presence of mutant hSOD1
is sufﬁcient for eliciting the suppression of cdk5 activity. Further
analysis of the muscle revealed a concomitant decrease in both MyoD
and cyclin D1 levels. These results suggest the presence of altered
muscle function in very young, presymptomatic G93A hSOD1 mice.
2. Materials and methods
2.1. Mice
G93A hSOD1 mice, wildtype hSOD1 trasgenic mice (WT hSOD1 mice), and non-
transgenic mice (Non-Tg mice) were obtained from the Jackson Laboratory (Bar Harbor,
ME). Mice were maintained on a 12-hour light/dark cycle with free access to food and
water. Genotyping was performed using genomic DNA, as suggested by the Jackson
Laboratory genotyping protocol. Mice were killed by decapitation at various ages and
spinal cord and triceps surae were quickly dissected. Dissected samples were either
ﬂash frozen for biochemical analysis or immersion-ﬁxed in 4% paraformaldehyde for
immunohistological analysis. The following numbers of animals were used for the
study: G93 hSOD1 mice at 27 days (n=7), 47 days (n=3), 67 days (n=3) of age; Non-Tg
age-matched controls at 27 days (n=7), 47 days (n=3), 67 days (n=3) of age;WT hSOD1
mice at 27 days (n=5) of age. All animal protocols were approved by the Animal Care
and Use Committee at the University of Washington (where the mice were generated
and initial experiments performed) and the Animal Care Committee at the University of
British Columbia.
2.2. Antibodies and reagents
Antibodies for cdk5 (J-3 and DC-17), SOD1 (G-11), cyclin D1 (DCS-6), MyoD (M-318),
p35 (c-19), PCNA (PC10), and cyclin B1 (GNS1) were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). The antibody for SOD1 (NCL-SOD1) was obtained from
Vector Laboratory (Burlingame, CA). Isotype-speciﬁc secondary antibodies conjugated
to HRP or biotin, and streptavidin-HRP were from Southern Biotechnology (Birming-
ham, AL); and Streptavdin-Alexa 488 and 594 were from Invitrogen (Carlsbad, CA).
2.3. Immunoﬂuorescence
Immunoﬂuorescence was performed on frozen muscle sample sections. Brieﬂy,
dissected muscle samples were immersion-ﬁxed for 20min at 4°C in 4% paraformalde-
hyde, embedded in Tissue-Tek O.C.T. compound (Sakura Finetek USA, Torrance, CA) and
stored in − 80°C until processing. Tissue blocks were cut at 10μm thickness on a cryostat,
mounted on glass slides, and stored at − 80°C. Indirect double immunoﬂuorescence
staining on sections was performed as follows. Brieﬂy, sections were thawed and the
area around the section was outlined using PAP pen (Research Products International,
Mount Prospect, IL). Sections were permeabilized using 0.25% Triton X-100 in TBS, and
blocked in 5% non-fat dry milk. Sections were incubated overnight at 4°C with the ﬁrst
primary antibody, followed by a 1-hour incubation in biotin-conjugated secondary
antibody at room temperature. The antigen was visualized by using streptavidin
conjugated with Alexa Fluor. This process was repeated for the second antibody. Co-
localization was determined using three different ﬂuorescents (Alexa 488, Alexa 594,and DAPI). Images were acquired using an Axioplan2 ﬂuorescence microscope (Carl
Zeiss Canada Ltd., Toronto, ON) equipped with a Cool Snap HQ CCD camera
(Photometrics, Tucson, AZ) and interfaced with a Dimension E520 computer (Dell
Canada Inc., North York, ON) using Metamorph image acquisition software (Version 6.1,
Molecular Devices, Downingtown, PA). The ﬁgures were assembled using Photoshop
(Version 7.0.1, Adobe Canada, Ottawa, ON).
2.4. Immunoblotting and immunoprecipitation
Western blotting was performed as reported [36] using supernatants from spinal
cord and triceps surae homogenates. In all experiments, protein levels were normalized
to levels of actin. For immunoprecipitations, supernatants from spinal cord and triceps
surae homogenates (100μg and 400μg, respectively) were incubated with 1.2μg of cdk5
antibody (J-3) overnight at 4°C and incubated with protein G-sepharose at 4°C for
1hour. After removing the supernatants and washing three times with TBS, samples
were electrophoresed, transferred to nitrocellulose (Protran, Schleicher and Schuell,
Dassel, Germany), and subjected to immunoblotting. Band density was analyzed using
Quantity One software (Biorad, Mississauga, ON).
2.5. Cdk5 immunoprecipitation kinase activity assay
Immunoprecipitation kinase activity assays were performed as described pre-
viously for cdk5 [37], with minor changes. Following protein G-sepharose incubation,
samples were washed twice with 700μl of cold TBS and once with 700μl of cold kinase
buffer. A reactionmix containing HEPES kinase buffer, 10μMATP,10μg of histone H1, and
0.5μCi of γ-32P-ATP was added to the samples and incubated at room temperature for
30min. Reactions were halted by adding loading buffer, and samples were electro-
phoresed on 12% SDS-PAGE gels. Histone bands were visualized by Coomassie blue
staining the gels, after which they were dried and apposed to a Kodak Biomax MS X-ray
ﬁlm. Band density was analyzed using Quantity One software (Biorad).
2.6. Large scale immunoisolation of mutant and wildtype human SOD1
Large scale immunoisolation of mutant and wildtype hSOD1 was performed on
brain lysate supernatants from G93A and wildtype hSOD1 transgenic samples using
hSOD1 antibody (G-11) covalently coupled to protein G support using a Seize X protein
G immunoprecipitation kit (Pierce, Rockford, IL). Eluted antigenwas concentrated using
microcon centrifugal ﬁlter devices (30kDa, Millipore, Bedford, MA). Protein concentra-
tions of concentrated immunoisolates were determined using a Qubit ﬂuorometer
(Invitrogen). Predetermined amounts of immunoisolate were added to 400μg of triceps
surae lysate supernatants from non-transgenic samples. Following incubation for 1hour
at 4°C, immunoprecipitation kinase activity assays were performed as described above.
2.7. Statistical analysis
One-way and two-way ANOVA with least-signiﬁcant-difference (LSD) post hoc test
was performed using Statistica (1999 Edition for Windows©, StatSoft, Inc., Tulsa, OK).
Unpaired Student's t-test was performed using Excel (2003 edition for Windows©,
Microsoft©, Redmond, WA).
3. Results
3.1. Reduced muscle cdk5 activity in very young presymptomatic G93A
hSOD1 mice
Neuromuscular denervation is observed in G93A hSOD1 mice as
early as 47 days of age [16]. Also, peripheral nerve injury in these mice
accelerates muscle function deterioration [21]. It has been shown that
muscle denervation resulting from nerve injury is accompanied by
upregulation of p35 expression and muscle cdk5 activity [35]. p35 is a
regulatory subunit of cdk5 [38]. To determine whether the early
muscle denervation process in G93A hSOD1 mice is reﬂected in
muscle cdk5 activity, we examined muscle cdk5 activity in G93A
hSOD1 and non-transgenic mice as early as three presymptomatic
time points: 27, 47, and 67 days of age.
Cdk5 immunoprecipitation kinase assay on triceps surae samples
from non-transgenic mice showed higher cdk5 activity at 27- and 47-
day time points compared to the 67-day time point (one-way ANOVA,
F2,7=6.65, p=0.02; Multiple comparison post hoc analysis (LSD test)
27- vs. 67-day [a vs. c], p=0.05; 47- vs. 67- day [b vs. c], p=0.01), but
such transient changes were not observed in the G93A hSOD1 mice
samples (Fig. 1). Two-way ANOVA analysis of cdk5 activities observed
in muscle samples from 27- and 47-day-old G93A hSOD1 and Non-Tg
mice revealed a statistically signiﬁcant genotype effect; wherein the
muscle samples from G93A hSOD1 mice displayed signiﬁcantly lower
Fig. 1. Age-dependent changes in cdk5 activity in triceps surae are absent in G93A
hSOD1 mice. Cdk5 activity in triceps surae samples from G93A hSOD1 and Non-Tg
littermates was examined at three different ages: 27 days, 47 days, and 67 days. A
statistically signiﬁcant age-dependent change in cdk5 activity was observed in the
muscle samples from Non-Tg littermates (one-way ANOVA, F2,7=6.65, p=0.02).
Multiple comparison post hoc analysis showed higher cdk5 activity in 27-day-old and
47-day-old mice compared to 67-day-old mice (27 days vs. 67 days [a vs. c], p=0.03;
47 days vs. 67 days [b vs. c], p=0.009, least square difference test). Such transient
change in cdk5 activity was not detected in themuscle samples fromG93A hSOD1 at the
ages tested (F2,7=0.454, p=0.65). The values in graphs are mean±SD.
Fig. 2. Genotype-dependent changes in cdk5 activity are observed in the absence of
changes in cdk5 and p35 protein levels. (A) Two-way ANOVA analysis of hindlimb
muscle samples from 27- and 47-day-old G93A hSOD1 and Non-Tg mice showed
signiﬁcant reduction in cdk5 activity in samples from G93A hSOD1 mice compared to
age-matched samples from Non-Tg mice (F1,10=10.11, p=0.009). Multiple comparison
post hoc analysis showed statistically signiﬁcant reduction in the cdk5 activity in
samples fromG93A hSOD1mice compared to Non-Tgmice at both 27 and 47 days of age
(27-day-old animal comparison: G93A hSOD1 vs. Non-Tg: p=0.04; 47-day-old animal
comparison: G93A hSOD1 vs. Non-Tg; p=0.04; least-signiﬁcant-difference test). Cdk5
activity in samples from 27-day-old G93A hSOD1mice also showed signiﬁcant decrease
compared to samples from 47-day-old Non-Tg mice (p=0.006; least signiﬁcant
difference test). In contrast, no deﬁcits were observed in cdk5 (B) and p35 (C) protein
levels. The values in graphs are mean±SD.
464 K.H.J. Park, I. Vincent / Biochimica et Biophysica Acta 1782 (2008) 462–468cdk5 activity compared to those from Non-Tg mice at these ages
(Fig. 2A, F1,10=10.11, p=0.009). Multiple comparison post hoc analysis
showed a 23% and 20% decrease in muscle cdk5 activity for 27- and
47-day-old G93A hSOD1 mice, respectively (27-day-old mice:
p=0.04; 47-day-old mice: p=0.04). Two-way ANOVA analysis on the
levels of cdk5 and p35 in these muscle samples did not show any
statistical signiﬁcance (Fig. 2B and C) suggesting that diminished cdk5
activity in G93A hSOD1mice at these ages is not due to altered levels of
either cdk5 or p35.
3.2. Mutant G93A hSOD1 suppresses muscle cdk5 activity in vitro
The signiﬁcant genotype effect on cdk5 activity at early ages suggests
thatmutantG93AhSOD1has a role in thedecreasedmuscle cdk5activity
in G93A hSOD1 mice. A recent study has shown that mutant huntingtin
protein interacts with cdk5, resulting in the suppression of cdk5 activity
[39]. Based on this ﬁnding, we surmised that the suppression of muscle
cdk5 activity in G93A hSOD1 mice may arise from an abnormal inter-
action between cdk5 and mutant G93A hSOD1. However, we could not
rule out the possibility that an aphysiological interaction between cdk5
and mutant G93A hSOD1may be observed as a result of human protein
overexpression. In order to distinguish between the mutant protein
effect andproteinoverexpressioneffect,weusedWThSOD1mice,which
lack any pathological phenotype, as a control.
Examination of the triceps surae samples from 27-day-old G93A
and WT hSOD1 mice showed that more mutant G93A than wildtype
hSOD1 co-immunoprecipitated with cdk5 (Fig. 3A; p=0.05). To
determine whether this interaction is tissue speciﬁc, we examined
spinal cord samples obtained from the same animals. When analyzed,
there was no difference between the amounts of mutant G93A and
wildtype hSOD1 co-immunoprecipitated with cdk5 in the spinal cord
samples (Fig. 3A). The increased amount of mutant G93A hSOD1
pulled down with cdk5 in muscle samples is likely to be a result of a
speciﬁc interaction with the mutant protein, as the overall expression
levels of the human transgene was lower in the G93A hSOD1
compared to WT hSOD1 muscle samples (Fig. 3B).
We then examined the cdk5 activity in these samples to determine
whether the amount of mutant hSOD1 interaction with cdk5 had an
effect on the kinase activity. Interestingly, the amount of mutant G93A
and wildtype hSOD1 pulled down by cdk5 was inversely correlated to
the cdk5 activity in triceps surae. Muscle cdk5 activity in the G93A
hSOD1 mice was 21% less than that of the WT hSOD1 mice (Fig. 3C;
p=0.001). No such difference in the cdk5 activity between the two
groups was detected in the spinal cord samples (Fig. 3C).To directly test whether the decreased cdk5 activity in the muscle
sample was indeed due to the presence of mutant hSOD1, we
introduced either the mutant G93A or WT hSOD1 to lysates of triceps
surae samples from non-transgenic animals. Mutant G93A and WT
hSOD1 were immunoisolated from brains using a monoclonal hSOD1
antibody (G-11). Muscle tissue was not used for immunoisolation as a
precaution against potential muscle-speciﬁc co-factors that may co-
immunoprecipitate with immunoisolates and potentially confound
the results.
The addition of mutant G93A hSOD1 immunoisolate to non-
transgenic triceps surae lysate resulted in a concentration-dependent
reduction in the cdk5 activity (Fig. 3D, one-way ANOVA, F5,11=6.8,
p=0.006). We observed a 30% decrease in cdk5 activity with the
addition of 3μg of mutant G93A hSOD1 immunoisolate (Fig. 3D,
p=0.05, post hoc LSD multiple comparison test). In contrast, the
addition of 3μg of wildtype hSOD1 immunoisolate to the lysate did not
result in suppression of cdk5 activity (Fig. 3D). These results suggest
Fig. 3. Mutant G93A hSOD1 suppresses cdk5 activity in muscle lysates. Cdk5 interaction with either mutant G93A or WT hSOD1 was examined in supernatants from muscle and
spinal cord lysate samples from 27-day-old G93A and WT hSOD1 transgenic mice. (A) More G93A hSOD1, compared to WT hSOD1, co-immunoprecipitated with cdk5 in the muscle
lysates (two-tailed Student's t-test; p=0.05). No increase in the interaction between mutant G93A hSOD1 and cdk5 was observed in spinal cord samples. (B) The greater interaction
betweenmutant G93A hSOD1 and cdk5 is not a consequence of higher protein expression. In contrast, the hindlimbmuscle lysates fromWT hSOD1mice showed higher hSOD1 levels
than those from G93A hSOD1 mice, suggesting higher expression level for WT hSOD1. (C) Examination of cdk5 activity in the same samples corresponding to (A) showed a decreased
cdk5 activity in G93A hSOD1muscle samples compared toWT hSOD1muscle samples (two-tailed Student's t-test; p=0.001). Again, no difference in the cdk5 activities was observed
between the spinal cord samples from G93A hSOD1 andWT hSOD1mice. (D) To determinewhether the presence of mutant G93A hSOD1 is responsible for the reduced cdk5 activity,
immunoprecipitates of either mutant G93A or wildtype hSOD1 were added to the supernatants of Non-Tg mouse muscle lysates prior to the immunoprecipitation kinase assay.
Immunoprecipitation kinase assay following the incubation with mutant G93A hSOD1 immunoisolated from brain resulted in a concentration-dependent reduction of cdk5 activity
(0 μg, n=6; 0.1 μg, n=1; 0.5 μg, n=2; 1 μg, n=2; 3 μg, n=3). Addition of 3 μg of WT hSOD1 (n=3) immunoisolated from brain to the supernatants of Non-Tg mouse muscle lysates did
not result in a reduction of the cdk5 activity (one-way ANOVA, F5,11=6.06, p=0.006, post hoc multiple comparison test, ⁎pb0.05). The values in graphs are mean±SD.
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suppression of endogenous cdk5 activity in triceps surae.
3.3. MyoD and cyclin D1 levels are reduced in G93A hSOD1 mouse
triceps surae
Although much of what we understand regarding cdk5 function is
derived from its role in the central nervous system, it has also been
shown to be associated with various muscle functions. In Xenopus, it is
involved in the regulation of muscle development [34]. In rats, cdk5
activity is upregulated in the hindlimb muscle following nerve injury
[35]. In C2 myoblasts, cdk5 activity is associated with, and positively
modulates, myogenic differentiation [33].
In order to determine whether the diminished cdk5 activity in
triceps surae of G93A hSOD1 mice reﬂects a potential myogenic
dysfunction in these animals, we examined the levels of MyoD. MyoD
is a well-deﬁned regulatory factor involved in myogenic determina-
tion and differentiation [40,41]. A comparison of muscle samples from
27-day-old G93A hSOD1 and Non-Tg mice usingWestern immunoblotassay revealed 61% less MyoD in G93A hSOD1 samples (Fig. 4A,
p=0.001, two-tailed t-test). The decreased MyoD levels in G93A
hSOD1 mice seem to suggest altered myogenic function in 27-day-old
G93A hSOD1 mice.
Since myogenesis in vivo involves proliferation of satellite cells,
leading to their fusion ontomaturemyoﬁbers [42,43], we also examined
the levels of various cell proliferation markers. The level of cyclin D1, a
marker for the G1 phase of the cell cycle, was 38% lower in the G93A
hSOD1 muscle (Fig. 4B; p=0.01, two-tailed t-test). Despite the
signiﬁcantly reduced level of cyclin D1, the levels of cdk4 (Fig. 4C),
PCNA (Fig. 4D), and cyclin B1 (Fig. 4E) in G93A hSOD1 mice were not
statistically different from the levels observed in non-transgenic mice.
Additionally, we did not detect any phospho-Rb in either the G93A
hSOD1 or non-transgenic muscle samples (data not shown). The lack of
changes in the levels for other proteinmarkers ofG1, S, andG2/Mphases
seems to suggest that the alteration of the cyclin D1 levels in themuscle
of G93A hSOD1 mice may reﬂect a cell-cycle independent event.
To better evaluate the association of cdk5 and mutant hSOD1 in
situ, and in the context of seemingly altered myogenic function, we
Fig. 4. Myogenic and G1 phase cell-cycle markers are altered in the muscle of G93A hSOD1 animals. Protein levels of a myogenic marker and various cell-cycle regulators were
examined in themuscle samples of 27-day-old G93A hSOD1 and Non-Tgmice. Protein levels for (A) MyoD and (B) cyclin D1, a G1 phase cell-cycle regulator, were signiﬁcantly lower in
the muscle samples from G93A hSOD1 compared to those from Non-Tg mice (two-tailed Student's t-test, p=0.001 and p=0.01, respectively). We did not detect any differences in the
protein levels for (C) cdk4, another G1 phase cell-cycle marker, (D) PCNA, an S phase cell-cycle regulator and (E) cyclin B1, a G2/M phase cell-cycle regulator, in the muscle samples
between the G93A hSOD1 and Non-Tg mice. The values in graphs are mean±SD.
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hSOD1 in muscle sections from G93A hSOD1 mice. A distinct nuclear
localization of cdk5 was detected via immunoﬂuorescence in muscle
ﬁbers (Fig. 5A). Mutant hSOD1 also showed nuclear localization, but at
a much reduced frequency relative to cdk5 (Fig. 5A). However, some of
the mutant hSOD1 staining showed clear co-localization with cdk5 in
nuclei (Fig. 5A; white arrows). We also noted signiﬁcant differences in
the distribution of DAPI stained nuclei between G93A hSOD1 and non-
transgenic muscle ﬁbers. Although a highly organized patterning of
nuclei was observed in muscle sections from non-transgenic mice
(Fig. 5B), the G93A hSOD1mice muscle sections were characterized by
a distribution of nuclei that was clustered and disorganized (Fig. 5B).
4. Discussion
In this report, we have highlighted biochemical changes in the
hindlimb muscle of 27-day-old G93A hSOD1 mice in comparison to
similar muscle samples from age-matched WT hSOD1 and Non-Tg
mice. Our results show reduced cdk5 activity in hindlimb muscle of
27-and 47-day-old G93A hSOD1 mice compared to their Non-Tg
littermates. Comparison of hindlimb muscle from 27-day-old G93A
andWT hSOD1mice using a co-immunoprecipitation assay revealed a
greater protein–protein interaction between cdk5 and mutant G93A
hSOD1. In vitro, a concentration-dependent decrease in cdk5 activity
mediated by mutant hSOD1 was observed. Furthermore, MyoD and
cyclin D1 levels were lower in hindlimbs of 27-day-old G93A hSOD1
mice compared to age-matched Non-Tg mice.
Past studies have shown evidence of early neuromuscular changes
in G93A hSOD1 mice that precede motor neuron loss. Muscle
denervation has been observed in these animals as early as 47daysof age [15,16,18]. Electrophysiological examination has revealed
decreases in muscle contractile force and functional motor units as
early as 40days of age [18,44]. Although axonal sprouting has been
reported in these mice [16,18], contractile force decline in coordina-
tion with the decline in motor unit numbers in G93A hSOD1 mice
suggests no functional compensation by sprouting [44]. Additionally,
altered muscle function in G93A hSOD1 mice is suggested by a study
showing accelerated muscle function deﬁcit following peripheral
nerve injury [21].
Nerve injury in normal muscle results in the activation and
proliferation of satellite cells. Denervation of normal muscle results
in the upregulation of MyoD in muscle ﬁber nuclei and satellite cells
[45–47]. In transgenic mice displaying localized IGF-1 overexpression
in skeletal muscle, nerve injury results in an enhancement of satellite
cell activation accompanied by MyoD and cyclin D1 upregulation, and
enhanced muscle reinnervation [25]. Interestingly, muscle-targeted
IGF-1 expression in G93A hSOD1 mice signiﬁcantly delayed disease
onset and progression [22,24]. On the other hand,myostatin inhibition
in G93A hSOD1 slowed muscle atrophy but did not delay disease
progression or rescue motor neurons [27]. Myostatin is known to
induce cyclin D1 degradation [48] and myostatin inhibition leads to
upregulation inMyoD [49] in muscle. Thus, the evidence suggests that
diminished MyoD and cyclin D1 levels in muscle are unlikely to play a
primary role in ALS, but may have an impact on the deterioration of
muscle function associated with the disease.
Another change that was observed in our study is the diminished
muscle cdk5 activity in G93A hSOD1 mice. Although the functional
role of cdk5 in the muscle is limited in knowledge compared to its role
in the central nervous system [28,29], cdk5 activity has been shown to
be upregulated during myoﬁber formation in C2 murine cells [33].
Fig. 5. Nuclear co-localization of cdk5 and mutant G93A hSOD1 in muscle sections. In
vitro analysis of muscle samples revealed a mutant hSOD1 interaction-mediated
reduction in cdk5 activity. Cdk5 and mutant hSOD1 localization were examined in
muscle sections to determine whether the observed interactions are detectable in situ.
(A) Nuclear staining of cdk5 is more widespread than that of mutant hSOD1. Only a
subpopulation of cdk5 positive nuclei showed mutant hSOD1 immunostaining. Triple
immunoﬂuorescence shows distinct co-localization of cdk5 and mutant hSOD1 in the
myonuclei. (B) Muscle ﬁbers in G93A hSOD1 mice show aberrant nuclear patterning
compared to those from Non-Tg mice. Nuclear patterning in the G93A hSOD1 mice
muscle was clustered and disorganized in appearance compared to Non-Tg mice as
shown by DAPI staining. Scale bar=50 μm.
467K.H.J. Park, I. Vincent / Biochimica et Biophysica Acta 1782 (2008) 462–468Accordingly, dominant negative cdk5 expression in these cells inhibits
myoblast differentiation [33]. In Xenopus embryos, dominant negative
cdk5 expression results in aberrant somitic muscle patterning, which
is accompanied by reduced MyoD expression [34]. Cdk5 activity has
also been shown to be upregulated in muscle following nerve injury
[35]. Thus, currently available research evidence of cdk5's role in
muscle suggests that it is involved in muscle regeneration and repair
mechanisms; diminished cdk5 activity at a very young, presympto-
matic age may result in an inappropriate muscle response to
progressive muscle denervation taking place in these mice. On the
other hand, p35 null/G93A hSOD1 doublemutantmice did not present
an enhanced disease phenotype [50]. It may be that in the muscle of
G93A hSOD1 mice, the additional reduction in cdk5 activity mediated
by p35 knock-out does not contribute further to the dysfunction.
Normally, cdk5 activity is much higher in spinal cord compared to
muscle. In our study we observed decreased cdk5 activity in the
muscle but not in the spinal cord of G93A hSOD1mice. In the study by
Takahashi and Kulkarni, only the cdk5 activity in the spinal cordsamples was measured [50] so we can only speculate about the
additional reduction of muscle cdk5 activity in these double mutant
mice. Perhaps the lack of effect in p35 null/G93A hSOD1 double
mutant mice may be due to a ﬂoor effect of cdk5 activity in muscle.
Additional p35 knock-out-mediated reduction of already lower cdk5
activity in muscle of G93A mice may not hasten disease progression.
Our in vitro analysis showed that the presence of mutant hSOD1
was sufﬁcient to reduce the cdk5 activity in the muscle lysate in a
concentration-dependent manner. However, a recent study by Miller
et al. showed that neither siRNA-mediated knock-down nor Cre
recombinase-mediated knock-out of mutant hSOD1 had any bene-
ﬁcial effect on the disease progression in these animals [12]. The lack
of an effect in their study could be due to the fact that the partial
knock-down of mutant hSOD1 is insufﬁcient in reducing the
deleterious actions of the mutant protein in the muscle. Also, Cre
recombinase-mediated knock-out in their study targeted only a subset
of cells in the muscle leaving open the possibility that the remaining
cells in the muscle may mediate some the mutant hSOD1 toxicity.
Even if the presence of mutant hSOD1 in the muscle does not directly
contribute to the disease progression, we speculate that postnatal
accumulation of mutant hSOD1 protein in muscle [51] may inhibit
cdk5 activity, which may in turn contribute to the acceleration of
muscle function deterioration in these mice following peripheral
nerve injury [21].
To our knowledge these are the earliest observed biochemical
changes in the hindlimb muscle of G93A hSOD1 mice. Diminished
levels of MyoD, cyclin D1 and cdk5 activity in the muscle suggest that
the muscle regenerative mechanisms may be defective in these
animals. Although the recent evidence suggests that the muscle does
not play a primary role in mediating mutant hSOD1 toxicity, the
deterioration of muscle function in response to denervation in these
animals may be enhanced by the early alteration of this intrinsic
muscle property. Through a deeper understanding of the mechanisms
underlying these biochemical changes and their impact on the
disease, it may be possible to delay the deterioration of muscle
function in the affected individuals and contribute positively to their
quality of life.
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